Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in
preclinical studies. The interplay of chemistry and materials has resulted in improved …

During the past two decades, the clinical use of biopharmaceutical products has markedly
increased because of their obvious advantages over conventional small-molecule drug …

Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense
potential in animal models of auto-and alloimmunity. However, the effective translation of …

Multidisciplinary research efforts in the field of drug delivery have led to the development of
a variety of drug delivery systems (DDS) designed for site-specific delivery of diagnostic and …

Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly
preclinically but also already in clinical trials. Combining nanomedicines with …

Chimeric antigen receptor (CAR) therapy has achieved remarkable clinical efficacy against
hematological cancers and has been approved by FDA for treatment of B-cell tumors …

In the past decade, we have witnessed the revolution in cancer therapy, especially in the
rapid development of cancer immunotherapy. In particular, the introduction of nanomedicine …

Immunotherapies have been accelerating the development of anti-cancer clinical treatment,
but its low objective responses and severe off-target immune-related adverse events (irAEs) …

With the rapid increase in the use of nanotechnology and immunotherapy for cancer
management in the recent past, there are great implications for using nanotechnology in …